SEC Form 4Coverage since Jun 1, 2026
$SNDX insider trading
Over the last 12 months, Syndax Pharmaceuticals insiders reported no purchases and 4 sales totaling $2.1M across SEC Form 4 filings. 50% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.1M 4 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 50% pre-arranged plans
Side
Price · $SNDX · 12Mvia TradingView
Top insiders · 12m
Metzger Michael AChief Executive Officer2× · $915K
Goldan Keith A.Chief Financial Officer1× · $22K
Botwood Nicholas A.J.Head of R&D, CMO1× · $1.2M
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | Metzger Michael AChief Executive Officer · O·D | ▼ Sale | 32,375 | $24.24 | $785K | -6.3% | plan |
| Jun 12, 2026 | Botwood Nicholas A.J.Head of R&D, CMO · O | ▼ Sale | 65,515 | $18.07 | $1.2M | -51.8% | plan · 2 tranches |
| Jun 1, 2026 | Goldan Keith A.Chief Financial Officer · O | ▼ Sale | 1,177 | $18.99 | $22K | -0.8% | — |
| Jun 1, 2026 | Metzger Michael AChief Executive Officer · O·D | ▼ Sale | 6,847 | $18.99 | $130K | -1.4% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $SNDX feed.